GlaxoSmithKline
5 Crescent Drive
Philadelphia
Pennsylvania
19112
United States
Tel: 888-825-5249
Website: http://www.gsk.com/
About GlaxoSmithKline
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2748 articles with GlaxoSmithKline
-
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
-
A new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
-
Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).
-
Two antimalarial strategies have been published from Imperial College London in the past month: new compounds that prevent the malaria parasite from infecting mosquitoes and gene-edited mosquitoes that cannot reproduce, leading to population destruction.
-
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
-
Fina Biosolutions Announces New Patent for Conjugate Vaccine Development
9/27/2018
Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM197 in E. coli.
-
GlaxoSmithKline (GSK) and the non-profit Aeras reported that their M72/AS01E vaccine candidate significantly cut the rate of pulmonary tuberculosis in HIV-negative adults with latent tuberculosis infection.
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
9/21/2018
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta
-
Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.
-
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
-
A second former GlaxoSmithKline scientist has pled guilty to stealing trade secrets as part of a scheme to benefit a startup China-based pharmaceutical company he helped establish.
-
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
-
AstraZeneca Plans to Seek Regulatory Approval for COPD Drug PT010 Following Phase III Trial
9/17/2018
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial on Sunday that showed its triple combination therapy PT010 outperformed its dual-therapy rivals eight of nine times. -
Pharnext: David Stout joins Pharnext's Board of Directors
9/17/2018
Pharnext SA announced the cooptation of David Stout as an independent Director of Pharnext.
-
September 14 Research Roundup: Brain in a Dish, Pathway Map for Diabetes, and “Finding Nemo’s” Ge...
9/14/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Tarveda Therapeutics Appoints Jeffrey Bloss, M.D. as Chief Medical Officer
9/12/2018
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
-
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.